Does the media favor TCRX or SGMT?

In the previous week, TScan Therapeutics had 7 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for TScan Therapeutics and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.94 beat TScan Therapeutics' score of 0.33 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TCRX or TARA?

In the previous week, TScan Therapeutics had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for TScan Therapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.33 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TCRX or CHRS?

In the previous week, TScan Therapeutics had 5 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for TScan Therapeutics and 4 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.97 beat TScan Therapeutics' score of 0.33 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UNCY or TCRX?

In the previous week, TScan Therapeutics had 3 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 9 mentions for TScan Therapeutics and 6 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.41 beat TScan Therapeutics' score of 0.33 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TScan Therapeutics (TCRX) Competitors

$0.97 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$0.91 -0.05 (-5.66%)

As of 06/26/2026 06:54 PM Eastern

Compare

TCRX vs. SGMT, TARA, CHRS, UNCY, and VYGR

Should you buy TScan Therapeutics stock or one of its competitors? MarketBeat compares TScan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TScan Therapeutics include Sagimet Biosciences (SGMT), Protara Therapeutics (TARA), Coherus Oncology (CHRS), Unicycive Therapeutics (UNCY), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does TScan Therapeutics compare to Sagimet Biosciences?

TScan Therapeutics (NASDAQ:TCRX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Sagimet Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Sagimet Biosciences' return on equity of -37.57% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Sagimet Biosciences has lower revenue, but higher earnings than TScan Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.13	-$129.77M	-$0.96	N/A
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

TScan Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 519.32%. Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 262.20%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, TScan Therapeutics had 7 more articles in the media than Sagimet Biosciences. MarketBeat recorded 9 mentions for TScan Therapeutics and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.94 beat TScan Therapeutics' score of 0.33 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TScan Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.42, indicating that its share price is 242% more volatile than the broader market.

Summary

Sagimet Biosciences beats TScan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Protara Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Protara Therapeutics' return on equity of -38.70% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Protara Therapeutics	N/A	-38.70%	-36.02%

TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

TScan Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 519.32%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 537.14%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protara Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.13	-$129.77M	-$0.96	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

In the previous week, TScan Therapeutics had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for TScan Therapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.33 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Protara Therapeutics beats TScan Therapeutics on 10 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Coherus Oncology?

TScan Therapeutics (NASDAQ:TCRX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Coherus Oncology has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.13	-$129.77M	-$0.96	N/A
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90

TScan Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 519.32%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 477.78%. Given TScan Therapeutics' higher probable upside, equities analysts clearly believe TScan Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Coherus Oncology	397.30%	-198.90%	-46.65%

TScan Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

In the previous week, TScan Therapeutics had 5 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for TScan Therapeutics and 4 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.97 beat TScan Therapeutics' score of 0.33 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coherus Oncology beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does TScan Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Unicycive Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Unicycive Therapeutics currently has a consensus target price of $24.75, suggesting a potential upside of 247.12%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 519.32%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Unicycive Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	287.19	-$26.56M	-$2.21	N/A
TScan Therapeutics	$10.32M	6.13	-$129.77M	-$0.96	N/A

In the previous week, TScan Therapeutics had 3 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 9 mentions for TScan Therapeutics and 6 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.41 beat TScan Therapeutics' score of 0.33 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TScan Therapeutics beats Unicycive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Voyager Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 359.61%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 519.32%. Given TScan Therapeutics' higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Voyager Therapeutics has a net margin of -319.61% compared to TScan Therapeutics' net margin of -1,360.61%. Voyager Therapeutics' return on equity of -55.97% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.37	-$119.72M	-$1.97	N/A
TScan Therapeutics	$10.32M	6.13	-$129.77M	-$0.96	N/A

In the previous week, TScan Therapeutics had 8 more articles in the media than Voyager Therapeutics. MarketBeat recorded 9 mentions for TScan Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.33 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Very Positive
TScan Therapeutics	Neutral

Voyager Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Summary

Voyager Therapeutics beats TScan Therapeutics on 10 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.31M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-1.01	21.75	26.14	24.17
Price / Sales	6.13	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.45	8.31	10.78	6.38
Net Income	-$129.77M	$23.92M	$3.58B	$337.00M
7 Day Performance	11.99%	1.93%	1.97%	-0.20%
1 Month Performance	-10.30%	-0.41%	-0.24%	-1.40%
1 Year Performance	-30.80%	65.22%	34.39%	27.76%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	4.1905 of 5 stars	$0.97 flat	$6.00 +519.3%	-30.8%	$63.31M	$10.32M	N/A	100	Gap Down
SGMT Sagimet Biosciences	3.0004 of 5 stars	$7.15 +0.7%	$25.57 +257.6%	-10.3%	$232.95M	$2M	N/A	8
TARA Protara Therapeutics	3.9183 of 5 stars	$4.12 +0.1%	$26.25 +537.9%	+43.1%	$230.70M	N/A	N/A	30	News Coverage
CHRS Coherus Oncology	3.7333 of 5 stars	$1.50 +1.0%	$8.67 +479.7%	+101.9%	$230.60M	$42.17M	0.90	330	Gap Up
UNCY Unicycive Therapeutics	3.0573 of 5 stars	$8.38 +6.5%	$24.75 +195.3%	+4.9%	$227.53M	$680K	N/A	9	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. SGMT, TARA, CHRS, UNCY, and VYGR

How does TScan Therapeutics compare to Sagimet Biosciences?

Summary

How does TScan Therapeutics compare to Protara Therapeutics?

Summary

How does TScan Therapeutics compare to Coherus Oncology?

Summary

How does TScan Therapeutics compare to Unicycive Therapeutics?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. SGMT, TARA, CHRS, UNCY, and VYGR

How does TScan Therapeutics compare to Sagimet Biosciences?

Is TCRX or SGMT more profitable?

Which has better earnings & valuation, TCRX or SGMT?

Do analysts rate TCRX or SGMT?

Do institutionals and insiders believe in TCRX or SGMT?

Does the media favor TCRX or SGMT?

Which has more risk & volatility, TCRX or SGMT?

Summary

How does TScan Therapeutics compare to Protara Therapeutics?

Do insiders and institutionals hold more shares of TCRX or TARA?

Is TCRX or TARA more profitable?

Which has more risk & volatility, TCRX or TARA?

Do analysts recommend TCRX or TARA?

Which has preferable valuation and earnings, TCRX or TARA?

Does the media prefer TCRX or TARA?

Summary

How does TScan Therapeutics compare to Coherus Oncology?

Do insiders & institutionals hold more shares of TCRX or CHRS?

Which has preferable earnings and valuation, TCRX or CHRS?

Do analysts prefer TCRX or CHRS?

Is TCRX or CHRS more profitable?

Which has more risk & volatility, TCRX or CHRS?

Does the media prefer TCRX or CHRS?

Summary

How does TScan Therapeutics compare to Unicycive Therapeutics?

Is UNCY or TCRX more profitable?

Do analysts recommend UNCY or TCRX?

Do institutionals & insiders hold more shares of UNCY or TCRX?

Which has more risk & volatility, UNCY or TCRX?

Which has higher valuation and earnings, UNCY or TCRX?

Does the media favor UNCY or TCRX?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Do analysts recommend VYGR or TCRX?

Is VYGR or TCRX more profitable?

Do institutionals and insiders have more ownership in VYGR or TCRX?

Which has stronger earnings and valuation, VYGR or TCRX?

Does the media favor VYGR or TCRX?

Which has more risk and volatility, VYGR or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools